235791-25-0

Upstream product

• 6802-76-2 ethyl 2-cyano-2-cyclohexylideneacetate 
• 235791-23-8 2-aza-spiro<4.5>decane-2,4-dicarboxylic acid 2-benzyl ester 4-methyl ester 
• 748118-43-6 2-benzyl-2-aza-spiro[4.5]decane-4-carboxylic acid 
• 235791-21-6 2-benzyl-2-aza-spiro<4.5>decane-carboxylic acid methyl ester 
• 235791-22-7 2-aza-spiro[4.5]decane-4-carboxylic acid methyl ester 
• 235791-24-9 2-aza-spiro<4.5>decane-2,4-dicarboxylic acid 2-benzyl ester 
• 1201-74-7 (R)-[1-(naphthalen-2-yl)ethyl]amine 

Relevant academic research and scientific papers

An in vitro investigation into conformational aspects of gabapentin

Conformational analysis of constrained cyclohexane systems was pioneered fifty years ago by Barton and Hassel. We now report an investigation based on a conformational analysis of a number of novel cyclohexane based Gabapentin analogues coupled with their in vitro evaluation at the Gabapentin binding site. These data are used to propose a possible binding conformation for Gabapentin. Copyright (C) 1999 Elsevier Science Ltd.

Synthesis and biological evaluation of conformationally restricted gabapentin analogues

A series of conformationally restricted Gabapentin analogues has been synthesised. The pyrrolidine analogue (R)-2-Aza-spiro[4.5]decane-4-carboxylic acid hydrochloride (3a) had an IC50 of 120nM, similar to that of Gabapentin (IC50 = 140nM), at the Gabapentin binding site on the α2δ subunit of a calcium channel. Compound (3a) also reversed carrageenan induced hyperalgesia in rats.